Navigation Links
Pharsight Signs Two New DMX(R) License Customers
Date:4/2/2008

f drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Forward Looking Statements

The statements in this press release related to the performance of Pharsight products are forward looking statements. Forward looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations may affect the demand for the product; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10Q filed with the Securities and Exchange Commission on February 14, 2008. All forward looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.

Registered Trademarks and Trademarks

Pharsight, Drug Model Explorer and DMX are registered trademarks of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharsight Achieves First License Sale for Public-Source Database
2. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
3. Pharsight Expands Strategic Consulting Services Team
4. Pharsight Hosts Fourth Annual PKS User Group Meeting
5. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
6. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
7. Pharsight Announces 1-For-3 Reverse Stock Split
8. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
9. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
10. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
11. Pharsight Achieves $7.4 Million in Quarterly Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... applications and designed for continuous operation up to 1500 bar. The sanitary design ... efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... SAN DIEGO, Dec. 13 BioMed Realty Trust, Inc.,(NYSE: ... I. Gilchrist to its,board of directors, increasing the board ... in the real estate industry, with a breadth of,ability ... large-scale commercial real estate projects. We believe that,Rick,s contributions ...
... Lesson as Prep for ... In-Person ... physician,comfort and knowledge with techniques around botulinum toxin injections,lead to ... Inc. (Solstice) has created MYOBLOC(TM) University, an,online, self-study resource that ...
... and PHILADELPHIA, December 13, The Board of Directors ... the global specialty biopharmaceutical company,today announces its Board ... retire as Non-Executive Chairman; Matthew Emmens (56) will ... be appointed Chief,Executive., These Board changes will ...
Cached Biology Technology:BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 3New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia 2New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia 3Shire plc: Board Changes 2Shire plc: Board Changes 3Shire plc: Board Changes 4
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik ... und findet vom 22. bis 25. Oktober 2015 ... Die Konferenz feiert in diesem ... ist die ICG weltweit zu einem der einflussreichsten ... eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... the University of Toronto describes a nanoscale material they've ... smaller digital devices and cellphones, and could even lead ... , The material, known as periodic mesoporous organosilica (PMO), ... of a metre across. The team created it by ...
... a molecular switch in mammals that shifts the body's fuel ... torpor in mice, a research team led by scientists at ... the Jan. 19 edition of Nature. , While ... note that the pivotal metabolic signal that emerged from the ...
... mother counts her newborn's fingers and toes, she probably ... baby's complete set of 20 digits. , Although ... substance responsible for clogging arteries, Vanderbilt University Medical Center ... an important developmental protein controls the development of fingers ...
Cached Biology News:Darkness unveils vital metabolic fuel switch between sugar and fat 2Darkness unveils vital metabolic fuel switch between sugar and fat 3Cholesterol gets 'thumbs up' for role in digit development 2Cholesterol gets 'thumbs up' for role in digit development 3
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Integrins Sampler Kit 10g each...
PKC Sampler Kit 10 mu g each...
Biology Products: